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Abstract
Systemic lupus erythematosus is a polymorphic and multigenic inflammatory autoimmune disease. Cyclic AMP (cAMP)
modulates inflammation and the inhibition of cyclic nucleotide phosphodiesterase type 4 (PDE4), which specifically
hydrolyzes cAMP, inhibits TNFa secretion. This study was aimed at investigating the evolution of PDE activity and expression
levels during the course of the disease in MRL/lpr lupus-prone mice, and to evaluate in these mice the biological and clinical
effects of treatments with pentoxifylline, denbufylline and NCS 613 PDE inhibitors. This study reveals that compared to CBA/
J control mice, kidney PDE4 activity of MRL/lpr mice increases with the disease progression. Furthermore, it showed that the
most potent and selective PDE4 inhibitor NCS 613 is also the most effective molecule in decreasing proteinuria and
increasing survival rate of MRL/lpr mice. NCS 613 is a potent inhibitor, which is more selective for the PDE4C subtype
(IC50 = 1.4 nM) than the other subtypes (PDE4A, IC50 = 44 nM; PDE4B, IC50 = 48 nM; and PDE4D, IC50 = 14 nM). Interestingly,
its affinity for the High Affinity Rolipram Binding Site is relatively low (Ki = 148 nM) in comparison to rolipram (Ki = 3 nM).
Finally, as also observed using MRL/lpr peripheral blood lymphocytes (PBLs), NCS 613 inhibits basal and LPS-induced TNFa
secretion from PBLs of lupus patients, suggesting a therapeutic potential of NCS 613 in systemic lupus. This study reveals
that PDE4 represent a potential therapeutic target in lupus disease.
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Introduction
Systemic lupus erythematosus (SLE) is a polymorphic and
multigenic autoimmune disease that predominantly affects wom-
en. The prevalence of lupus in the UK ranges from 40 cases per
100,000 people among northern Europeans to more than 200
cases per 100,000 people in the black population [1]. This
inflammatory disease is characterized by the presence of anti-
double stranded DNA marker antibodies in the serum of patients
and by characteristic lupus nephropathy inducing chronic renal
failure. There is no specific treatment for this pathology, which is
addressed with symptomatic treatments, such as corticoids and
immunosuppressant [2,3].
Cyclic AMP (cAMP) is a key intracellular second messenger,
which is an important modulator of inflammation. Downstream
receptor activation, intracellular signalling is regulated by cyclic
nucleotide phosphodiesterase families (PDE1 to PDE11) that
hydrolyze cAMP and cGMP as a feedback mechanism to return to
basal levels, then mediating cAMP-dependent and cGMP-
dependent protein kinase activation [4]. Among PDEs, the
members of the PDE4 family (PDE4A, 4B, 4C and 4D) specifically
hydrolyse cAMP and are mainly present in inflammatory cells [5].
Studies performed with mice deficient in PDE4B demonstrated
that this PDE4 family member plays an essential role in TNFa
production by peripheral leukocytes and macrophages [6,7].
Therefore, one could question about the possible participation of
PDE4 family members in SLE. This study was designed for
investigating the PDE4 expression and activity in MRL/lpr lupus-
prone mice and for examining in vivo the effects of PDE4 inhibitors
on SLE disease progression.
Modifications of cAMP metabolism have been investigated in
the kidneys of MRL/lpr lupus-prone mice as the disease
progressed by assessing PDE4 activity and expression, PDE4
being the major PDE isozyme regulating cAMP level. The effects
of pentoxifylline [8], denbufylline [9,10] and NCS 613 [11] that
differently inhibit PDE4 activity have been studied both in vivo in
treated animals and ex vivo, by testing lipopolysaccharide (LPS)-
induced TNFa secretion by peripheral blood lymphocytes (PBLs).
NCS 613 effect was also analyzed ex vivo on LPS-induced TNFa
secretion by PBLs from patients with SLE. This study reveals that
PDE4 represents a potential therapeutic target in SLE disease and
that NCS 613 treatment delays lupus progression.
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Results
Evolution with disease progression of cAMP-PDE
activities in the kidneys of MRL/lpr mice
cAMP-PDE activities were assessed in the kidneys of MRL/lpr
lupus-prone mice at two time points of the disease progression,
namely at 8 weeks, before major changes in survival rate,
proteinuria and serum anti-double-stranded DNA antibody levels
occur, and at 18 weeks, characterized in this strain by high levels
of proteinuria present in 70% of mice and serum anti-DNA
antibodies occurring in 90% of animals [12]. Haplotype-matched
CBA/J normal mice of the same age were used as control. The
pattern of cAMP-PDE activities in kidney extracts of 8 week-old
CBA/J mice shows that cAMP hydrolysis is essentially under the
control of PDE4 (66%), while PDE2 and PDE3 contribute only for
26% and 8%, respectively (Figure 1). Total cAMP-PDE activity is
significantly modified (Figure 2A), as analyzed with a two-way
ANOVA test (age phenotype: P=0.0159, F=9.287; disease
phenotype: P=0.0002, F=41.20; interaction: P=0.0042,
F=15.61). Eight week-old MRL/lpr mice display levels of total
cAMP-PDE activity that are similar to those measured in control
mice (Figure 2A). In contrast total cAMP-PDE activity levels in the
kidneys of 18 week-old MRL/lpr lupus-prone mice are increased
by 41% (P,0.001) and 24% (P,0.01) compared with 18 week-old
CBA/J control and with 8 week-old MRL/lpr lupus-prone mice,
respectively (Figure 2A). This increase is not due to PDE2 or
PDE3 (Figures 2B and 2C) but rather to PDE4 (Figure 2D). PDE4
activity is significantly modified (Figure 2D), as analyzed with a
two-way ANOVA test (age phenotype: P=0.0148, F=9.575;
disease phenotype: P=0.0302, F=6.91; interaction: P=0.0116,
F=10.58). PDE4 activity levels in the kidneys of 18 week-old
MRL/lpr lupus-prone mice are increased by 27% (P,0.01) and
30% (P,0.01) compared with the 18 week-old CBA/J control and
with the 8 week-old MRL/lpr lupus-prone mice, respectively
(Figure 2D). The changes on PDE4 activity are related to disease
progression and not to a simple effect of aging, since no significant
alteration was seen between the 8th and 18th week in CBA/J
controls.
Evolution with disease progression of PDE4 protein
expression in the kidneys of MRL/lpr mice
To further explore PDE proteins in MRL/lpr lupus-prone mice,
kidney extracts were subjected to SDS-PAGE and PDE proteins
were analyzed by Western immunoblotting using kidney extracts
from CBA/J mice as control. Figure 3 shows that variants of the
four PDE4 subfamilies are expressed at different levels in the
kidney extracts of 8 week-old CBA/J control mice (quantification
in Table 1). Among the variants of the four PDE4 subtypes, several
display statistically different expression levels as analyzed with a
two-way ANOVA test (Figure 4): (i) PDE4A-60 kDa (age
phenotype: P=0.034, F=6.845; disease phenotype: P=0.0216,
F=11.09; interaction: P=0.0083, F=13.23); (ii) PDE4B-101 kDa
(age phenotype: P=0.0007, F=28.06; disease phenotype:
P=0.0019, F=20.50; interaction: P=0.0127, F=10.23); (iii)
PDE4C-81 kDa (age phenotype: P=0.9282, F=0.008641; disease
phenotype: P,0.0001, F=6015; interaction: P=0.9282,
F=0.008647); and (iv) PDE4D-72 kDa (age phenotype:
P=0.0361, F=6.326; disease phenotype: P,0.0001, F=75.30;
interaction: P=0.0508, F=5.272). In the kidneys of 8 week-old
MRL/lpr mice (L8), the expression of PDE4A-60 kDa protein
(87% increase, P,0.01; Figure 4A), PDE4B-101 kDa (63%
decrease, P,0.01; Figure 4B), PDE4C-81 kDa (undetectable,
P,0.001; Figure 4C), and PDE4D-72 kDa (33% decrease,
P,0.01; Figure 4D) is affected compared to CBA/J kidneys
(C8). In 18 week-old MRL/lpr lupus-prone mice (L18), while
PDE4A-60 kDa and PDE4B-101 kDa expression returns to a level
similar to CBA/J controls (C18), PDE4C-81 kDa protein remains
undetectable (P,0.001) and PDE4D-72 kDa expression remains
significantly decreased (258%; P,0.001). Again, these effects are
not simply linked to aging, since no significant changes are seen
between 8 and 18 week-old CBA/J controls (C8 and C18). It is
noticeable that PDE4B-101 kDa expression is significantly in-
creased during the course of the lupus disease (P,0.001, Fig. 4B).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression
is stable in all samples (Figure 4, right panel).
Effect of PDE4 inhibitors on disease progression of MRL/
lpr mice
MRL/lpr lupus-prone mice have been treated with PDE
inhibitors with different selectivity and specificity toward PDE4,
namely pentoxifylline characterized by a lack of PDE isoform
selectivity, denbufylline displaying a higher selectivity for PDE4,
and NCS 613 characterized by a high selectivity for PDE4 and a
strong potency (Tables 2 and 3). MRL/lpr mice were injected
intravenously (i.v.) with either 30 mg NCS 613, 100 mg denbufyl-
line, or 100 mg pentoxifylline, or the vehicle only. They were
monitored regularly for renal disease (checked by the proteinuria
level) and survival. Although no significant effect was seen on the
level of DNA antibodies measured in the serum of treated mice,
animals that received two of the three PDE4 inhibitors (i.e.
pentoxifylline and NCS 613) developed a proteinuria level that
was significantly lower compared to the control group
(Figures 5A,B,C). NCS 613 was the most effective inhibitor in
delaying proteinuria. The first mouse that developed proteinuria
in the NCS 613 group was 18 week-old (Figure 5C, P=0.005
compared to the control group) while at the same age, around
50% of mice treated with pentoxifylline or denbufylline and 70%
of untreated mice had positive proteinuria.
More importantly, only the administration of NCS 613
significantly increased survival of MRL/lpr mice (Figure 5F,
P=0.005). Mice treated with NCS 613 started dying later, at 26
weeks vs. 17 weeks in the control group and 22 and 15 weeks in the
Figure 1. Pattern of cAMP-PDE activities in the kidneys of 8
week-old CBA/J control mice. cAMP-PDE specific activities in total
homogenate and contribution of PDE2, PDE3 and PDE4 were assessed
as described in the Methods section. Data are expressed as pmol/min/
mg of protein and are the mean6s.e.m. of the data obtained from three
individual mice.
doi:10.1371/journal.pone.0028899.g001
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pentoxifylline (Figure 5D) and denbufylline (Figure 5E) groups,
respectively. At 31 weeks, 50% of NCS 613-treated mice were still
alive, when the median survival time for mice treated with PBS,
pentoxifylline or denbufylline was 22.5, 27.5 and 26.5 weeks,
respectively.
Effect of PDE4 inhibitors on LPS-induced TNFa secretion
by PBLs from MRL/lpr mice
To assess the impact of different PDE4 inhibitors on LPS
activation of cytokine responses, PBLs isolated from treated
MRL/lpr mice were incubated with 5 mg/mL LPS and the
levels of TNFa were measured in culture supernatants 24 h
later. As shown in Figure 6, LPS stimulation induced high levels
of TNFa secretion by PBLs from MRL/lpr mice that received
vehicle only. Interestingly, LPS-induced TNFa production was
significantly decreased in the cultures of PBLs from MRL/lpr
mice treated with PDE4 inhibitors (P,0.05). The calculated
inhibition rate of TNFa secretion was in the same range in all
groups (51% for pentoxifylline, 70% for denbufylline and 54%
for NCS 613).
Figure 2. Evolution with the disease of cAMP-PDE activities in the kidneys of MRL/lpr mice. cAMP-PDE specific activities in total
homogenate (A) and contribution of PDE2, PDE3 and PDE4 (B–D) were assessed on 8 week-old (C8) and 18 week-old (C18) CBA/J control mice and 8
week-old (L8) and 18 week-old (L18) MRL/lpr mice as described in the Methods section. Data are expressed as pmol/min/mg of protein and are the
mean6s.e.m. of the data obtained from three individual mice. **, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0028899.g002
Figure 3. Protein expression pattern of PDE4 in the kidneys of 8 week-old CBA/J control mice. PDE4A, PDE4B, PDE4C, and PDE4D protein
expression was assessed on 8 week-old CBA/J control mice as described in the Methods section. The apparent size of protein bands is expressed in
kDa.
doi:10.1371/journal.pone.0028899.g003
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Effect of NCS 613 on LPS-induced TNFa secretion by PBLs
from SLE patients
We then extended our studies to assess the effect of NCS 613 on
LPS-induced TNFa secretion by PBLs from lupus patients. In
general, the latter have blood disorders and particularly leucope-
nia and lymphopenia. This feature precludes performing complete
dose-response measurements ex vivo. Therefore, in a preliminary
experiment we selected a sample for which we could benefit from a
sufficient number of cells to determine the amount of NCS 613
required in this assay. As expected, after 24 h incubation, LPS
induced a marked production of TNFa by PBLs from this patient
(patient SLE1; 1035691 pg/ml vs 1566 pg/ml without LPS),
and this production was significantly suppressed by 1 and 10 mM
of NCS 613 (P=0.01 and 0.008 respectively; Figure 7A). No effect
was seen at a lower NCS 613 concentration (0.1 mM). The
following tests were thus performed using 10 mM of NCS 613
(Figure 7B). NCS 613 significantly inhibited 70 to 98% of LPS-
induced TNFa production from PBLs originated from SLE
patients (SLE1, P=0.008; SLE2, P=0.005; SLE3, P=0.0002).
NCS 613 also decreased the basal TNFa secretion level by 67% in
the case of cells from patient 2 (P=0.0004; Figure 7C).
Determination of NCS 613 Ki value on
3H-rolipram
binding site
Rolipram was the first specific PDE4 inhibitor chemically
synthesized. Since most of the rolipram analogs and rolipram itself
induce emesis, and since this effect was found to be related to their
interaction with the so-called High Affinity Rolipram Binding Site
(HARBS; [13–16]), we investigated the capacity of NCS 613 to
displace 3H-rolipram binding on HARBS. While the Ki value of
rolipram toward 3H-rolipram binding on rat brain membrane was
3 nM (2.4 to 3.9 nM), the Ki value of NCS 613 on HARBS was
148 nM (113 to 196 nM) (Figure S1).
Effects of pentoxifylline, denbufylline and NCS 613 on
PDE1-PDE5 isozymes
Denbufylline is a structural analogue of pentoxifylline with
some substitutions on the xanthine ring while NCS 613 is an
adenine analogue (Table S1). The three molecules have a very
low pKa (,1.7). At physiological pH, there is only protonation
state and all three are neutral. All three molecules were shown to
have moderate lipophilicity (log D7.4 values 0.27–3.78;Table S1)
indicating they have a good balance between solubility and
permeability. Table 2 compares the potency and selectivity of
these compounds. Pentoxifylline is a poor PDE inhibitor acting in
1025–1024 molar range concentration, displaying a higher
selectivity for PDE5 compared to PDE4 (PDE5$PDE3$P-
DE2=PDE4.PDE1) with an IC50 value of 74 mM for PDE5
and a PDE5/PDE4 ratio value of 0.55 indicating a better
selectivity for PDE5 than for PDE4. Denbufylline is a better PDE
inhibitor than pentoxifylline, displaying a higher selectivity for
PDE4 (PDE4.PDE5.PDE1.PDE2..PDE3) with an IC50
value of 0.76 mM for PDE4 and a PDE5/PDE4 ratio value of
7.11. Compared to pentoxifylline, the substitutions on the
xanthine ring of denbufylline are able to reverse the PDE
isozyme selectivity (PDE5 for pentoxifylline and PDE4 for
denbufylline) and to produce a much higher potency toward
PDE4 (IC50 values of 135 and 0.76 mM for pentoxifylline and
denbufylline, respectively). NCS 613 is the most potent (IC50
value of 0.042 mM; [11]) and the most selective (112-fold
relatively to PDE5 and 930-fold relatively to PDE1) PDE4
inhibitor.
Effects of pentoxifylline, denbufylline, NCS 613 on human
recombinant PDE4 subtypes
The PDE4 family comprises PDE4A, PDE4B, PDE4C and
PDE4D proteins. As the PDE4D-knocked-out mice developed
emesis more easily compared to the wild-type mice, PDE4D
inhibition seemed to favor emesis [17]. Therefore, we investigated
the subtype PDE4 selectivity of pentoxifylline, denbufylline and
NCS 613 (Table 3, Figure S2). As expected, pentoxifylline
inhibited PDE4 subtypes in high concentration ranges (1025–
1024 M) with IC50 values order: PDE4D<PDE4B,PDE4A,P-
DE4C. Denbufylline inhibited more potently PDE4 subtypes in
the 1027–1026 M concentration range with IC50 values order:
PDE4B<PDE4A,PDE4D,PDE4C. Interestingly, NCS 613
selectively inhibited PDE4C with an IC50 value of 1.4 nM, in
comparison with PDE4D-IC50 (14.4 nM), PDE4A-IC50 (44 nM)
and PDE4B-IC50 (48 nM) (Table 3, Figure S2). Furthermore, it
should be noticed that both pentoxifylline and denbufylline, which
are xanthine analogues, poorly inhibited PDE4C subtype in
comparison to other PDE4 subtypes.
Discussion
The experiments described here in MRL/lpr lupus-prone mice
aimed at defining the therapeutic potential of PDE4 inhibitors in
this autoimmune disease, which is characterized by nephropathy
and inflammatory processes. It is well established that PDE4
inhibitors are anti-inflammatory drugs [15] and that PDE4
inhibitors are beneficial in nephropathy [18], suggesting that
PDE4 inhibitors might be helpful for prevention and treatment of
SLE.
This study reveals that both the appearance of proteinuria and
the survival time of NCS 613-treated MRL/lpr mice are
significantly delayed. For obvious reasons of timing, the effect of
Table 1. Distribution of PDE4A, PDE4B, PDE4C and PDE4D variants in the kidneys of 8 week-old CBA/J control mice.
PDE4A PDE4B PDE4C PDE4D
kDa % kDa % kDa % kDa %
123 16.661.0 101 29.161.1 81 99.960.7 76 32.861.7
85 6.560.9 78 12.860.5 72 24.560.7
77 17.560.5 85 20.860.3 51 42.661.5
60 30.760.5 72 37.261.6
50 28.561.4
Data are expressed as the percentage of the sum of all signals expressed in each subfamily and represent the mean6s.e.m. of three independent experiments.
doi:10.1371/journal.pone.0028899.t001
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NCS-613 was not evaluated in strains of mice of different
haplotypes such as MRL+/+, B6/lpr or (NZBxNZW)F1 mice that
develop a spontaneous disease that is significantly slower
compared to MRL/lpr mice. It is worth noting also that compared
to these mouse models, MRL/lpr mice develop a very strong lupus
disease and therefore that any improvement of their clinical and
biological signs is highly significant. Our recent data have shown
that MRL/lpr mice represent excellent model for translational
studies from mice to human [12,19].
First, we characterized PDE isozyme profile in renal tissue of
normal mice and investigated changes in activity and expression in
MRL/lpr mice, a mouse model developing a severe lupus disease.
In the kidneys of CBA/J mice, PDE4 was found to be the main
contributor of cAMP hydrolytic activity, whereas PDE2 and
PDE3, which both hydrolyze cAMP and cGMP, contribute to a
lower extend. No change with age in total cAMP-PDE activity was
seen in 8 and 18 week-old control mice. However, a significant
increase (+41%, P,0.001) in total cAMP-PDE activity in 18 week-
Figure 4. Protein expression pattern of PDE4 in kidneys of MRL/lpr mice of 8 and 18 weeks. PDE4A, PDE4B, PDE4C, PDE4D and GAPDH
protein expressions were assessed on 8 week-old (C8) and 18 week-old (C18) CBA/J control mice and 8 week-old (L8) and 18 week-old (L18) MRL/lpr
mice. Data are the mean6s.e.m. of three mice.*, P,0.05; **, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0028899.g004
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old MRL/lpr mice was seen that was associated to a significant
increase in PDE4 activity (+30%, P,0.01), indicating that lupus
disease specifically alters PDE4 in kidney. Western immunoblot-
ting analysis of PDE4 subtypes revealed the presence of multiple
variants in PDE4A, PDE4B and PDE4D families and one variant
for PDE4C contributing in total PDE4 activity, attesting the
preponderant and complex participation of PDE4 s in renal
functions in which multiple micro-compartmentation of these
variants might regulate specific processes [4,20]. Changes in PDE4
variant expression were observed in MRL/lpr mice. Interestingly,
the expression of PDE4B-101-kDa increases with the disease and
might partially contribute to the increase in PDE4 activity. Indeed,
PDE4 activity was raised in 18 week-old mice and the expression
of only one PDE4 variant in each subtype family was decreased. It
should be noticed that PDE4A-60-kDa represent only 30% of
detected PDE4A expression, PDE4B-101-kDa represent only 29%
of detected PDE4B expression and PDE4D-72-kDa represent only
24% of detected PDE4D expression. A decrease of the expression
of these variants might contribute only weakly to total PDE4
activity. Interestingly, PDE4C-81-kDa expression was undetect-
able in the renal tissue of MRL/lpr mice even in young mice. At
this stage, it is difficult to raise any definitive conclusion on the
possible consequences of this drop of PDE4C-81 kDa protein
detection. An hypothesis could be that PDE4C is altered in a way
that would change its antigenic properties, explaining the lack of
recognition by antibody. The contribution of PDE4C into PDE4
activity is considered as minor although it has never been really
addressed. It should be noticed that PDE expression does not
necessarily reflect PDE protein activity, since some post-transla-
tional modifications occur in PDEs, notably PKA-dependent
phosphorylation, which might increase PDE4 activity [4,20,21].
This question is difficult to solve as no potent and selective PDE4
subtype inhibitor allowing assessing PDE4 subtype contribution in
PDE4 activity is available [22].
Our data thus show for the first time that in the kidneys of 18
week-old MRL/lpr mice there is a global increase of PDE4
activity. This prompted us to study the therapeutic potential of
PDE4 inhibitors in this mouse model of lupus. Three kinds of
compound inhibiting PDE4 were chosen: an anti-inflammatory
compound, pentoxifylline, delivered on the pharmaceutical market
as TorentalH that has previously been studied in MRL/lpr mice
[23] and mice with 16/6 Id-induced experimental lupus [24];
denbufylline, a xanthine analogue of pentoxifylline known as
PDE4 inhibitor [9,10] with anti-TNFa property [25,26] and NCS
613, an adenine analogue, designed and synthesized in our
laboratory. NCS 613 is a potent and selective inhibitor of PDE4
[11], which induces in vivo and ex vivo anti-inflammatory effects
[27,28]. We recently showed in human lung tissues that NCS 613
significantly decreased PDE4 activity and reduced I-KBa
degradation with a lower expression level of PDE4B and PDE4C
[29]. NCS 613 inhibits LPS-induced TNFa secretion by human
PBLs with an IC50 value of 18 nM [27]. Interestingly, our present
data on PDE4 subtypes show that NCS 613, an adenine analogue,
is selective for PDE4C and point out that both pentoxifylline and
denbufylline, which are xanthine analogues, act differently from
NCS 613 on PDE4C since they act very poorly on PDE4C
subtypes in comparison to the other PDE4 subtypes.
This study reveals that both the appearance of proteinuria and
the survival time of NCS 613-treated mice are significantly
delayed. Therefore, in agreement with our previous data obtained
in rat kidney with rolipram [18], protective effect of NCS 613 may
be linked to its high selectivity and potency for PDE4. We cannot
rule out however that in vivo, NCS 613 interacts with several PDE4
subtypes (PDE4C.PDE4D.PDE4A=PDE4D) and that NCS
613 restores the PDE4C protein expression. NCS 613 has a direct
effect on cAMP degradation but it might also induce long-term
changes in PDE4 regulation or expression, as previously shown
with rolipram [30].
TNFa secretion that participates in inflammatory processes
characterizes lupus progression. Interestingly, denbufylline, pent-
oxifylline and NCS 613 treatments of MRL/lpr mice significantly
decrease LPS-induced TNFasecretion measured ex vivo. Denbufyl-
Table 2. IC50 (mM) values for pentoxifylline, denbufylline and NCS 613 on PDE1-PDE5 isozymes.
Isozyme PDE1 PDE2 PDE3 PDE4 PDE5 PDE5/PDE4
Substrate Modulator cGMP CaM cAMP cGMP cAMP cAMP cGMP
Pentoxifylline 236620 119610 8467 135611 7466 0.55
Denbufyllline 133611 208619 .300 0.7660.05 5.460.5 7.11
NCS 613 3962 2463 .300 0.04260.003 4.760.1 111.9
IC50 values were determined at 1 mM substrate concentration in the presence of the modulator for PDE1 and PDE2 and represent the mean6s.e.m. of three
independent experiments. CaM= calmodulin.
doi:10.1371/journal.pone.0028899.t002
Table 3. IC50 (mM) values for pentoxifylline, denbufylline and NCS 613 on human recombinant PDE4 subtypes.
PDE4A PDE4B PDE4C PDE4D
Pentoxifylline 99
(91–109)
61
(54–69)
216
(191–244)
45
(37–57)
Denbufylline 0.23
(0.22–0.25)
0.17
(0.15–0.18)
1.21
(1.07–1.37)
0.45
(0.41–0.50)
NCS 613 0.0436
(0.0354–0.0538)
0.0481
(0.0443–0.0523)
0.0014
(0.0012–0.0016)
0.0144
(0.0118–0.0175)
IC50 values were determined at 1 mM cAMP substrate concentration and are given with their confident intervals.
doi:10.1371/journal.pone.0028899.t003
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line, pentoxifylline and NCS 613 display the same effectiveness,
keeping in mind that due to its limit of solubility, NCS 613 was
given at a three-fold lower dose than the other two drugs. NCS
613 (10 mM) also significantly decreases LPS-induced TNFa
secreted by PBLs from unselected patients with SLE. NCS 613,
decreases also by 67% the level of basal TNFa secretion,
suggesting that NCS 613 might have some potential in the
treatment of SLE.
PDE4 inhibitors elicit a number of side-effects, notably emesis,
thus limiting their therapeutic potential. Human area postrema and
other nuclei related to the emetic reflex express PDE4B and PDE4D,
and thus cAMP-signalling modification in the area postrema could
mediate the emetic effect of PDE4 inhibitors in human brain stem
[31]. The side-effects concern might be alleviated for example by the
design of small-molecule allosteric modulators of PDE4D that do not
completely inhibit enzymatic activity [32], by the finding of
Figure 5. Pentoxifylline, denbufylline and NCS 613 treatment effects on proteinuria and survival rate of MRL/lpr mice. Four groups of
MRL/lpr mice were injected via the i.v. route at 5, 7, 9 and 13 weeks with either 100 mL of PBS-10% ethanol (control, n = 10), or 100 mg pentoxifylline in
100 mL PBS-10% ethanol (n = 10), or 100 mg denbufylline in 100 mL PBS-10% ethanol (n = 10), or 30 mg NCS 613 in 100 mL PBS-10% ethanol (n = 8).
Proteinuria was measured as described in the Methods section at weeks 10, 14, 18 and 20 are represented for each mouse. Each symbol represents an
individual mouse and horizontal lines indicate the median. Closed symbols represent PBS-treated mice and open symbols represent inhibitors-treated
mice (pentoxifylline, denbufylline and NCS 613). Because PBS-treated-MRL/lpr mice present a high mortality, dead mice were considered to have a
proteinuria .2000 mg/dL (the level measured the week before their death). Survival rate is expressed as the percentage of surviving mice with time
expressed in weeks. *, P,0.05; **, P,0.01, ns; not significant.
doi:10.1371/journal.pone.0028899.g005
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compounds with high potency such as roflumilast [33] and GEBR-
7b [34]. An important finding in our work was to demonstrate that,
in contrast to rolipram, NCS 613 which efficiently inhibits PDE4
hydrolytic activity, displays a relatively weak ability to bind HARBS.
Our result strengthens our previous data showing that NCS 613 does
not induce acid gastric secretion [27]. Also, in opposite to rolipram
and other PDE4 inhibitors [15], it suggests that NCS 613 might
induce very low emetic effects in agreement with the proposal of
Souness and Rao [35] and the correlation observed between dose
required to induce emesis and that to occupy HARBS [36].
Since we showed that changes in PDE4 s occur in murine lupus
and that NCS 613 significantly delayed lupus development, we
questioned whether NCS 613 could affect specific PDE4 subtypes.
Our study on recombinant PDE4 s reveals that NCS 613 potently
and selectively inhibits PDE4C subtype (IC50 value of 1.4 nM). Most
interestingly NCS 613 targets the PDE4 variant that was found
particularly altered in lupus disease, opening a possible avenue for
investigation. This low-molecular weight chemical compound
(,500 Da) presents also the advantage to be easily administrated
and was shown to be active in vivo per os on inflammation [27].
In conclusion, this study shows for the first time, to our
knowledge, that PDE4 activity is increased in lupus conditions and
that among the different PDE4 inhibitors tested, NCS 613, a
highly selective PDE4C inhibitor, significantly prevents disease
progression by decreasing proteinuria, lowering ex vivo TNFa
secretion by PBLs and increasing animal survival rate. NCS 613
also inhibits basal and LPS-induced TNFa secretion by PBLs from
SLE patients. Although future investigation is warranted to clarify
the exact molecular actions of NCS 613, the present data indicate
that NCS 613 might have a potential for treating lupus patients.
Materials and Methods
Materials
cAMP and cGMP were from Sigma (St. Louis, MO, USA).
[8-3H] cAMP (25–40 Ci/mmol; 1 mCi/mL) and [8-3H] cGMP (5–
15 Ci/mmol; 1 mCi/mL) were purchased from Perkin Elmer
(Courtaboeuf, France) and purified by thin layer chromatography
on silica gel, using isopropanol/NH4OH/H2O (70/15/15) as a
solvent [37]. Tritiated rolipram (23 Ci/mmol; 5 mCi/mL) was a
gift from Celltech Therapeutics Society (Slough, UK). Calmodulin
was purified from bovine brain as described [38]. Denbufylline and
pentoxifylline were generous gifts from Beecham-Wulfing (Gronau,
Germany) and Hoechst (Puteaux, France), respectively. NCS 613,
cilostamide and rolipram were synthesized as described previously
[11,39,40]. Anti-PDE4A (AC55) and anti-PDE4B (K118) antibod-
ies [41] were a gift of Dr Marco Conti (Stanford University, USA).
Anti-PDE4C (PD4-301AP) and anti-PDE4D (PD4-401AP) anti-
bodies were from FabGennix (Frisco, TX, USA) and anti-GAPDH
antibody was from Chemicon (Billerica, MA, USA). Horseradish
peroxidase-conjugates were from Promega (Charbonnie`res-les-
Bains, France). ECL kit was from GE Healthcare (Orsay, France).
Animals
Female CBA/J (H-2k) and MR/lpr (H-2k) mice were purchased
from Harlan (Gannat, France). The animal experimentation was
conducted according to the ‘‘Principles of Laboratory Animal
Care’’ and with the approval of the Regional Ethics Committee of
Strasbourg (CREMEAS, project nuAL/05/08/03/07)
SLE Patients
Blood samples were obtained from three unselected patients
with SLE. The latter fulfilled the American College of Rheuma-
tology criteria for the disease. All samples were obtained from
volunteers attending the Rheumatology Clinic of Strasbourg
University Hospitals and were collected during routine clinical
(diagnostic/prognostic/therapeutic) procedures. Informed verbal
consent was obtained from each individual in agreement with the
Helsinki declaration and French legislation (article L1221-8-1),
under which no approval by an ethical committee was required in
this case. Patients were treated by low doses (median dose 10 mg;
range 0–20 mg) of methotrexate, hydroxychloroquine and/or
non-steroid anti-inflammatory drugs.
Treatment of lupus-prone mice with PDE inhibitors
A preliminary experiment was performed to investigate the
effects of the compounds as well as the influence of the solvent
PBS-10% ethanol administrations by the i.v. route. Mice were
monitored regularly during 2 weeks following administration and
sacrificed for organ observation. No deleterious effects were
observed in these conditions of administration.
Four groups of five week-old female MRL/lpr mice were
injected via the i.v. route at 5, 7, 9 and 13 weeks with either
100 mL of PBS-10% (v/v) ethanol (control, n = 10), or 100 mg
pentoxifylline in 100 mL PBS-10% ethanol (n = 10), or 100 mg
denbufylline in 100 mL PBS-10% ethanol (n = 10), or 30 mg NCS
613 in 100 mL PBS-10% ethanol (n = 8); in these conditions, NCS
613 was not soluble at 100 mg/100 mL.
All mice were monitored regularly for different clinical and
biological parameters over 26 weeks. Measurements of outcome
included the evaluation of survival and proteinuria measured on a
fresh urine sample. Protein levels were determined using colored
strips (Albutix; Bayer Diagnostics, Basingstoke, UK) and scored at
values corresponding to 30, 100, 300 and .2000 mg/dL.
Measurement of LPS-induced TNF-a secretion by PBLs
from MRL/lpr mice
Blood samples were pooled from groups of seven 14 week-old
treated mice. PBLs were purified by density separation (Lympho-
lyte-M, d= 1.0875; Cedarlane, Hornby, Canada), washed three
Figure 6. PDE inhibitor treatment effects on ex vivo LPS-
induced TNFa secretion by PBLs from MRL/lpr mice. Four groups
of 7 MRL/lpr mice each were injected i.v. at 5, 7, 9 and 13 weeks with
either 100 mL of PBS-10% ethanol (control), or 100 mg pentoxifylline in
100 mL PBS-10% ethanol, or 100 mg denbufylline in 100 mL PBS-10%
ethanol, or 30 mg NCS 613 in 100 mL PBS-10% ethanol. Blood samples
were collected from 14 week-old treated mice. PBLs pooled from seven
mice of each group were purified and cultured in the presence of LPS,
and TNFa secretion was determined by ELISA 24 h later. The results are
expressed as the mean concentration (pg/mL) 6s.e.m. of duplicate
cultures. *, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0028899.g006
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times, and resuspended at 56106 cells/ml in L-alanyl-L-glutamine-
enriched RPMI 1640 medium (Cambrex, Verviers, Belgium)
containing 10% (v/v) fetal calf serum (Dutscher, Brumath, France),
HEPES, gentamycin and b-mercaptoethanol. They were cultured
in duplicate using 56105 cells/well in the presence of 5 mg/mL LPS
from E. coli. Culture supernatants were collected after 24 h and
stored frozen at 220uC. TNFa levels were determined using a
double-sandwich ELISA (PharMingen, San Diego, CA; detection
limit 30 pg/mL) according to the manufacturer’s instructions.
Measurement of TNFa secreted by PBLs from SLE
patients
PBLs were isolated by centrifugation on Ficoll-Histopaque
(Sigma-Aldrich) and cultured as described above using 56105
cells/well. PBLs were incubated for 45 min with or without 10 mM
NCS 613, then stimulated or not with 5 mg/mL LPS. Culture
supernatants were collected 24 h later and stored frozen at 220uC
before TNFa level determination, as described above.
Preparation of kidney extracts
CBA/J andMRL/lpr mice were sacrificed by cervical dislocation
at 8 and 18 weeks. Kidneys were isolated, immediately frozen in
liquid N2 and stored at 280uC. Frozen kidneys were powdered-
ground in liquid nitrogen using a mortar/pestle set-up. The
resulting tissue-powders were homogenized with a glass-glass potter
for 3630 sec at 4uC in the following buffer: 20 mM Tris, pH 7.5,
5 mM EGTA, 150 mM NaCl, 20 mM Na b-glycerophosphate,
1 mM H-89, 10 mM NaF, 1 mM NaVO3, 1% (v/v) Triton X-100,
0.1% (v/v) Tween 20, 166 mM Pefabloc, 133 mM aprotinin,
8.3 mM bestatin, 2.5 mM E64, 3.3 mM leupeptin and 1.6 mM
pepstatin A. The homogenates were centrifuged at 14,000 g for
10 min at 4uC and the supernatants were stored as aliquots at
280uC until used. Protein concentration was determined following
Lowry et al. [42] using a compatible detergent assay.
Measurement of PDE activity in kidney extracts
PDE activity was determined with a radioenzymatic assay as
described previously [37]. Total cAMP-PDE activity was assessed
at 1 mM cAMP and the contribution of PDE isozymes was
determined by using selective inhibitors, 1 mM cilostamide for
PDE3 and 10 mM rolipram for PDE4, the residual cAMP-PDE
activity representing essentially PDE2. Specific activities were
expressed as pmol.min21.mg21 protein.
Analysis of protein expression pattern of PDE4
Proteins (30 mg) from kidney extracts were subjected to Western
immunoblotting as described previously [30]. Briefly, protein
Figure 7. Effect of NCS 613 on LPS-induced and basal TNFasecretion by PBLs from SLE patients. PBLs from three patients with SLE (SLE1,
SLE2 and SLE3) were purified and cultured as described in Materials and Methods. PBLs from SLE1 patient were incubated for 45 min with increasing
doses of NCS 613 and stimulated with 5 mg/mL of LPS (A). PBLs were incubated for 45 min with (%) or without (&) 10 mM of NCS 613 and stimulated
(B; SLE1, SLE2 and SLE3) or not (C; SLE2) with 5 mg/mL of LPS. TNFa secretion was determined by ELISA. The results are expressed as the mean
concentration (pg/mL) 6s.e.m. of duplicate cultures. There was no basal TNFa secretion in the culture of PBMCs from SLE1 and SLE3 patients.
*, P,0.05; **, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0028899.g007
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samples were denatured and solubilized for 5 min at 95uC in
Laemmli buffer, subjected to electrophoresis on SDS-8% poly-
acrylamide gel and electrotransferred onto polyvinylidene fluoride
membranes. Immunodetection was carried out with anti-PDE4A
(AC55; 1/2,000), anti-PDE4B (K118; 1/2,000), anti-PDE4C (PD4-
301AP; 1/2,500), anti-PDE4D (PD4-401AP; 1/2,500), and anti-
GAPDH (1/60,000) antibodies. Immobilized antigens were detect-
ed by chemiluminescence using horseradish peroxidase-labelled
secondary antibodies (1/60,000), an ECL kit and autoradiography
films. Autoradiography signals were captured on a GeneGenius Bio
Imaging System (Syngene/Ozyme, Saint Quentin Yvelines, France)
using the GeneSnap software and analyzed using the GeneTools
software (Syngene/Ozyme). Data are expressed in pixel units.
Measurement of IC50 on purified PDE isoforms
PDE1, PDE3, PDE4 and PDE5 were isolated by anion exchange
chromatography from bovine aortic smooth muscle cytosolic
fraction [43]. PDE2 was isolated from human platelets following
the method described in [44]. Purified PDEs were stored as small
aliquots at 280uC until use. PDE activity was determined at a
substrate concentration of 1 mM cAMP or cGMP in the presence of
10,000 cpm [3H]-cAMP or -cGMP as tracers. PDE1 activity was
assessed at 1 mM cGMP in calmodulin-activated state (18 nM
calmodulin with 10 mMCaCl2). PDE2 activity was assessed at 1 mM
cAMP in activated state (+5 mM cGMP), and PDE3 and PDE4
activities were assessed at 1 mM cAMP in the presence of 1 mM
EGTA. To prevent reciprocal cross-contamination between PDE3
and PDE4, the assays were carried out in presence of 50 mM
rolipram for PDE3 or 50 mM cGMP for PDE4. PDE5 activity was
measured at 1 mM cGMP in the presence of 1 mM of EGTA.
Denbufylline, pentoxifylline and NCS 613 were dissolved in
dimethyl sulfoxide (DMSO). The final concentration of DMSO
did not exceed 1% (v/v) for PDE activity assessment. This
concentration of DMSO had no effect when tested in control
preparation. Denbufylline, pentoxifylline and NCS 613 IC50 values
were also determined on human recombinant PDE4A, PDE4B,
PDE4C and PDE4D kindly given by Ted J. Torphy (SmithKline
Beecham Pharmaceuticals, King of Prussia, PA, USA).
The concentration of compounds that produced 50% inhibition
of substrate hydrolysis (IC50) was calculated by non-linear
regression analysis (GraphPad Prism, San Diego, CA) of
concentration-response curves including at least 6 different
concentrations of inhibitors.
3H-rolipram binding assay
Binding assays were performed on rat brain membranes with a
modification of the method of Schneider et al. [45]. The assay was
done in 50 mM N-Tris hydroxymethyl methyl-2-aminoethane
sulfonic acid/NaOH buffer, pH 7.6, containing 10 mM MgCl2,
0.1 M NaCl and 100 mM 59AMP. The final volume of reaction
mixture was 400 mL containing 4 nM 3H-rolipram. For saturation
binding, the concentration of 3H-rolipram ranged from 0.3 to
12 nM. Non-specific binding was determined in the presence of
1 mMunlabeled rolipram in the incubation medium. Binding assays
were started by the addition of 100 mL of rat brain membrane
(0.9 mg protein/mL) to the reaction mixture and conducted at
23uC for 1 h under agitation and stopped by the addition of 3 mL of
ice-cold reaction buffer and rapid vacuum filtration through
Whatman GF/B filters that have been soaked in 0.3% (v/v)
polyethylenimine. Filters were washed twice (3 ml of ice-cold
reaction buffer without 59AMP), dried and counted by liquid
scintillation. Non-specific binding was consistently lower than 20%
of the specific binding. 3H-rolipram was bound with high affinity
(Kd=1.4.60.2 nM) with an Hill number= 1.0460.05. Ki and
confidence interval values of binding studies were determined by
using one site fit Ki GraphPad Prism5 analysis.
Evaluation of pKa and logD7.4 values of denbufylline,
pentoxifylline and NCS 613
pKa and log D7.4 values were determined by classical
procedures by the ‘‘plateforme de Chimie Biologique Inte´grative
de Strasbourg-Technologies du me´dicament’’ (PCBiS; http://
www.pcbis.fr/).
Statistical analysis
PDE activity and expression data are expressed as mean6s.e.m.
from three independent experiments and analyzed with the two-way
ANOVA test with the Bonferroni post-test. TNF-a secretion data
were analyzed with the Student’s t-test for unpaired data. Survival
data were analyzed by the Kaplan-Meier product-limit method, with
analysis by log rank test. Significance was defined as P#0.05.
Supporting Information
Table S1 Chemical structures and some characteristics
of pentoxifylline, denbufylline and NCS 613. The pKa and
logD7.4 values were determined as described in Materials and
Methods.
(TIFF)
Figure S1 Effects of rolipram (N) and NCS 613 (&) on3H-rolipram binding were determined as indicated in
Materials and Methods.
(TIFF)
Figure S2 Effects of pentoxifylline (A), denbufylline (B)
and NCS 613 (C) on human recombinant PDE4 subtypes:
PDE4A (N), PDE4B (&), PDE4C (.) and PDE4D (¤).
IC50 values were determined as indicated in Materials
and Methods.
(TIFF)
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